Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer - Miles, David W.; Chan, Arlene; Dirix, Luc Y.; Cortés, Javier; Pivot, Xavier; Tomczak, Piotr; Delozier, Thierry; Sohn, Joo Hyuk; Provencher, Louise; Puglisi, Fabio; Harbeck, Nadia; Steger, Guenther G.; et al. (Journal of clinical oncology, 2010)
Gesehen am 26.04.2023